Tumor immune checkpoints (TICs) such as PDCD1 (PD-1), CTLA4, IDO1, and CD40 are critical regulators of immune responses and have emerged as promising therapeutic targets in cancer immunotherapy (18). The gene discussed is IDO1; the disease is neoplasm.